SOUTH SAN FRANCISCO, Calif., June 2, 2025 — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company focused on discovering and developing targeted therapies, has announced its participation in upcoming investor relations events.
2025 Jefferies Global Healthcare Conference
Wednesday, June 4th, 2025 at 8:10 AM ET
- A fireside chat with President and Chief Executive Officer Yujiro S. Hata, hosted by Maury Raycroft, Ph.D., Equity Research Analyst, Biotechnology.
Goldman Sachs 46th Annual Global Healthcare Conference 2025
Monday, June 9th, 2025 at 10:40 AM ET
- A fireside chat with President and Chief Executive Officer Yujiro S. Hata, hosted by Corinne (Jenkins) Johnson, Vice President, Equity Research, Biotechnology.
A live audio webcast of the conference events will be available in the “Investors/Events” section of the IDEAYA website at , contingent on permission from the conference host, and/or through the conference host. The webcasts will be available for replay for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA Biosciences is an oncology company focused on precision medicine, dedicated to the discovery and development of targeted therapeutic options for patient populations selected through the use of molecular diagnostics. IDEAYA integrates capabilities in identifying and validating translational biomarkers alongside drug discovery to select patient populations who are most likely to benefit from targeted therapies. IDEAYA is leveraging its early research and drug discovery capabilities in synthetic lethality, an emerging class of precision medicine targets.
Forward-Looking Statements
This press release includes forward-looking statements, including statements pertaining to participation in and/or presentations at certain investor relations events. IDEAYA assumes no responsibility to update or revise any forward-looking statements. For a comprehensive description of potential risks and uncertainties that may cause actual results to deviate from those expressed in the forward-looking statements, as well as risks pertaining to IDEAYA’s business generally, refer to IDEAYA’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
SOURCE IDEAYA Biosciences, Inc.
“`